Multidrug Resistant Tuberculosis Clinical Trial
Official title:
GRACE-TB：NGS-guided Regimens of Anti-tuberculosis Drugs for the Control and Eradication of MDR-TB
Tuberculosis (TB) has been one of the top 10 causes of death worldwide from a single
infectious agent, ranking above HIV/AIDS. Management and eradication of this disease is being
hindered by the emergence of multidrug-resistant TB (MDR-TB) and extensively drug resistant
TB (XDR-TB). Globally, there were estimated 10.4 million cases of TB and 490,000 cases of
MDR-TB in 2016. China accounts for around 8.6% (0.895/10.4 million) of the global TB burden,
ranking third in the top 3 countries (India, Indonesia, China) with the highest number of TB
cases and ranking first with the largest number of MDR/ Rifampin-Resistant (RR)-TB cases. The
treatment success rate for MDR-TB using the 18-24-month conventional World Health
Organization (WHO) regimen was estimated to be about 54% worldwide and 41% for China in 2016,
which remains unacceptably low.
The poor MDR-TB treatment success rates suggest that current drug regimens are suboptimal. In
addition, they are costly with a high pill burden, as many drugs, with significant potential
for adverse events, are given for a long duration. These factors also inhibit good treatment
compliance with further negative impact on treatment outcomes. According to previous studies,
treatment outcomes of MDR-TB could be affected by drug resistance of pivotal drugs in MDR-TB
regimen, such as fluoroquinolones, second-line injectable agents and pyrazinamide. The
available drug-resistance information could help physicians decide the proper regimens for
MDR-TB patients, which may prevent the useless prescription and evitable adverse.
Therefore, the individualized regimen based on the resistance profile of the bacteria and
patients' drug tolerance should be aimed for high-quality treatment for MDR-TB in the future.
A precision individualized treatment approach based on the rapid molecular drug
susceptibility tests of second line drugs may assist clinicians in making more suitable
regimen and improve the treatment outcome of MDR-TB. Also, precision regimen offers the
opportunity to improve treatment of drug-resistant tuberculosis through reduced toxicity
while reducing the risk of resistance amplification and further transmission at a population
level.
The purpose of this research is to assess the feasibility and effects of individualized
regimen that is guided by rapid molecular drug susceptibility tests of key second-line drugs
through next generation sequencing. Meanwhile, the study will evaluate a short course
regimens of drugs among "simple MDR-TB" patients who are proven to be sensitive to
fluoroquinolones ,injectable second-line drugs and pyrazinamide.
The GRACE-TB study is a multi-center, open-label, randomized, controlled trial in patients
with MDR-TB. This study will assess the feasibility and effects of individualized regimen for
MDR-TB based on rapid molecular drug susceptibility tests（DSTs） of key second-line drugs
through next generation sequencing (NGS) and try to improve the treatment outcome of MDR-TB.
And the study will evaluate a shorter course regimen among patients who are proven to be
sensitive to fluoroquinolones (FQs) or second-line injectable drugs(SLIDs) or pyrazinamide
(PZA) through NGS.
A total of 488 participants with MDR-TB will be recruited and followed up until 18 months
after the end of treatment. During randomization, eligible patients will be assigned in a 1:3
ratio to one of the following groups: a control group, which is treated with WHO-approved
MDR-TB regimen, composed of 6 months of PZA, amikacin (Am) ,moxifloxacin (MFX), prothionamide
(PTO), and Cycloserine (Cs), followed by 18 months of PZA, MFX, PTO and Cs; a NGS-guided
group, which is treated with one individualized regimen that is guided by the drug
susceptability test results of FQs/PZA/ SLIDs through NGS.
About 366 patients will be enrolled in the NGS-guided group. Based on the molecular DST
results of FQs/PZA/ SLIDs , patients proven to be sensitive to PZA, FQs and SLIDs will be
divided into to the "simple MDR-TB group" and those with resistant to at least one of
FQs/PZA/ SLIDs will be divided into to "complicated MDR-TB group".
Patients in the "simple MDR-TB group" will be assigned randomly in a 1:1 ratio to one of the
following daily regimen: a 9-month regimen(Regimen A) which consists of 4-month intensive
therapy of PZA, Am, MFX,PTO, Cs, followed by 5-month consolidation therapy of PZA, MFX, PTO
and Cs; a 12-month regimen(Regimen B) which consists of 6-month intensive therapy of PZA, Am,
MFX,PTO, Cs, followed by 6-month consolidation therapy of PZA, MFX, PTO and Cs.
Patients in the "complicated MDR-TB group" will be treated a regimen (Regimen C) in which the
resistant drug(s) will be replaced by the other WHO recommended drugs for MDR-TB such as
linezolid, clofazimine or ethambutol based on the DST results. The duration of treatment in
the "complicated MDR-TB group" is consistent with control group, with 6 months of intensive
phase and 18 months of consolidation phase.
The primary objective is to compare the proportion of patients with a favorable efficacy
between the NGS-guided group and the control group. The second objective is to assess whether
the proportion of simple MDR-TB patients with a favorable efficacy outcome of Regimen A is
not inferior to Regimen B. The participants will be followed up to 18 months after the end of
the treatment. The data accrued to 18 months after the end of treatment will be used in
primary and secondary analyses.
Safety evaluations performed are the routine lab tests, blood glucose, hearing, vital signs,
electrocardiograph (ECG), reporting of adverse events, physical examinations and chest CT.
Adverse events will be monitored and promptly managed during the whole treatment course.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05017324 -
Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment Trial
|
N/A | |
| Active, not recruiting |
NCT02496572 -
Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis in Uzbekistan
|
Phase 3 | |
| Completed |
NCT03942354 -
Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial
|
||
| Completed |
NCT02454205 -
An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05081401 -
Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)
|
||
| Completed |
NCT01856634 -
Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis
|
Phase 1 | |
| Active, not recruiting |
NCT03867136 -
Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)
|
Phase 4 | |
| Not yet recruiting |
NCT04484129 -
MDR-TB Close Contacts Tracing in China (TCCT Study)
|
||
| Completed |
NCT00727844 -
Linezolid to Treat Extensively-Drug Resistant Tuberculosis
|
Phase 2 | |
| Completed |
NCT01859923 -
A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)
|
Phase 2 | |
| Active, not recruiting |
NCT04421495 -
Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China
|
Phase 4 | |
| Active, not recruiting |
NCT04717908 -
Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS
|
N/A | |
| Recruiting |
NCT02120638 -
Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide
|
Phase 3 | |
| Recruiting |
NCT05534750 -
Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB)
|
Phase 2 |